Reliance’s Strand Life Sciences patents a blood-based technology for early cancer detection, enhancing accuracy and accessibility.
Reliance's Strand Life Sciences patents a liquid biopsy platform for early cancer detection using AI and cfDNA analysis in ...
In a significant step towards advancing early cancer detection in India, Strand Life Sciences, a subsidiary of Reliance ...
Asianet Newsable on MSN
Reliance's Strand Life Sciences patents blood test for early cancer
Reliance's Strand Life Sciences has been granted an Indian patent for its platform enabling early cancer detection from a ...
Caris Life Sciences ® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine ...
The next breakthrough in cancer screening is emerging from the convergence of artificial intelligence and canine biology. That’s the thesis behind SpotitEarly, a startup that recently launched in the ...
In a significant breakthrough for cancer diagnostics, Reliance Industries subsidiary Strand Life Sciences has secured an Indian patent for an artificial intelligence-powered technology that can detect ...
PreOncology today announced the launch of the nation's first medical-grade, oncologist-led cancer prevention and early detection program, introducing an emerging subspecialty of medical oncology ...
Patented platform uses cell-free DNA analysis and machine learning to detect cancer early and identify tissue of origin from ...
The patented platform combines high-quality genome sequencing, rigorous quality control, biologically informed methylation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results